Summary
Background Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal disorder with a variable disease trajectory. The aim of this study was to assess the potential of neutrophil-to-lymphocyte ratio (NLR) to predict outcomes for people with IPF.
Method We adopted a two-stage discovery and validation design using patients from the UCL partners (UCLp) cohort. For the discovery analysis, we included 71 patients from UCLH. In the validation analysis, we included 928 people with IPF, using real-life data from UCLH and 5 other UK centres. Data were collected from patients presenting over a 13-year period with a mean follow up time of 3.7 years.
Findings In the discovery analysis, we showed that values of NLR (<2.9 vs >/=2.9) were associated with increased risk of mortality (HR 2.04, 95% CI 1.09-3.81; p=0.025). In the validation cohort we confirmed this association of high NLR with mortality (HR 1.65, 95% CI 1.39-1.95; p<0·0001) and showed incorporation of baseline NLR in a modified GAP-stage/index (GAP/index)-plus improved predictive ability
Interpretation We have identified NLR as a widely available test that significantly correlates with lung function, can predict outcomes in IPF and refines clinical GAP-staging. NLR may help ILD specialist centres prioritise at risk patients in a timely way, even in the absence of lung function.
Competing Interest Statement
PMG reports consultant fees from Boehringer Ingelheim (BI) and AstraZeneca (AZ) and lecturing honoraria from BI, Roche and Cipla. ER reports lecturing fees from BI and Mundipharma. JCP reports consulting fees from Carrick therapeutics, AZ and lecturing honaria from The Limbic.
Funding Statement
This work was supported by Breathing Matters, and undertaken at Exeter, Leicester, Imperial and UCLH/UCL BRCs who receive a proportion of funding from the Department of Health`s NIHR Biomedical Research Centres funding scheme. TAM held an independent studentship from GSK. TN held a joint studentship from the Cystic Fibrosis Trust and the British Lung Foundation (SS19/06) JCP had an MRC New Investigator Award (MR/K004158/1). AD was supported in part by grant MR/N0137941/1 for the GW4 BIOMED MRC DTP, awarded to the Universities of Bath, Bristol, Cardiff and Exeter from the Medical Research Council (MRC)/UKRI. CJS was supported by an MRC grant (MR/V002538/1). RW was supported by an NIHR Academic Clinical Fellowship.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
ETHICAL APPROVALS AND FUNDING Ethical approval (and any ensuing amendments) was granted by the London - Harrow Research Ethics Committee. (REC reference: 18/LO/0937). Site specific and local R&D approvals were granted by each participating hospital site. The study was sponsored by University College London (UCL).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
